Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Bullboard Posts
Comment by Defaulteron Nov 02, 2018 9:23am
46 Views
Post# 28913250

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TRPX 48 million BO

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TRPX 48 million BOThanks, but I simply want to know how many shares outstanding, fully diluted, are held by Therapix. That they can answer.

StuinSea wrote:

Hey Guys IR is not going to be of any help:

Hello,
Thank you for supporting and investing in FSD Pharma.  Unfortunately, I cannot comment on the exact number of shares for the purchasing transaction.  It’s early to determine accurate numbers for valuations and any decisions made based on the deal, is at your own discretion.
 
Thanks,
IR
 
Sent from Mail for Windows 10
 


From: [FSD Webmail] <IR@fsdpharma.com>
Sent: Wednesday, October 31, 2018 3:41:27 PM
To: investor relations
Subject: FSD Pharma Webform "Number of TRPX shares."
 
From: Stuart
Subject: Number of TRPX shares.

Message Body:
Hi,

I own 260k Of FSDDF and 750 shares of TRPX. My question is how many total shares of TRPX will be purchased by FSD Phama? There seems to be some question on the exact number. I really hope you'll be able to clarify this for me.

Sincerely,
xxx

--
This e-mail was sent from a contact form on FSD Pharma


 

Defaulter wrote: I emailed therapix IR. I'll report back if they bother to respond.
 

 

Defaulter wrote: Someone might wanna call/email IR for therapix to confirm fully diluted share count.


Defaulter wrote: Yep. and any would-be investors in trpx, keep in mind, the ~$13 sp is based on the more obvious 3.5M shares o/s. If not fully dilted, that price decreases. I can't help but think it is trading based on the 3.5M; if the price gets to $13 and then another share count emerges, gonna be some unhappy investors.


Bella923 wrote: Exactly, and right now trpx is trading at a premium only because of the pending deal. But based on the SP and the proposed price of 13.74 is only about 20% abritage suggesting to me that the smart money is not buying this. To many moving parts. Bottom line is, IMO, you should not be buying up trpx for the purpose of an abritage 2x value. I would treat both companies independent as part of my due diligence valuation and consideration
Defaulter wrote: Yep. The binding letter of intent still allows for proper due diligence on both sides. So even if they don't like something for one reason or another, either could walk away.

Bella923 wrote: Exactly, that's why I said to me, I treat the SP and movement of FSD and trpx as 2 independent company. With this deal annoucement, I find it hard for the trpx SP to go over the fully diluted shares/48 million. I'm assuming inside their LOI clause, there would be some outs and time frame. If trpx has any material information such as pending clinical trial that is positive that would rocket their share price to $20/share, they can kill the deal and go on their own
Defaulter wrote: Theoretically, since no deal has been finalized, the trpx share price could trade to $20 tomorrow and it wouldn't matter in the least.


Defaulter wrote: They are being paid in FSD shares; and they can't contro the trpx share price. The deal was announced already, so the trpx share price now is irrelevant.


Bella923 wrote: If your figures are correct them fully diluted would be 48 million/8.3 million which works out to be $5.78/trpx share. That doesn't seem correct. No way in hell we are buying a company with market cap of $56 million for 48 million and all on share exchanges
Defaulter wrote: If we use the 'Total Equity' figure from the latest balance sheet entry I posted, 8.3M x $6.79US, assuming that is correct the market cap is $56M US fully diluted right now vs the 48M US we are paying.


Renofund wrote:
Bella923 wrote: Market cap has nothing to do with total diluted shares. Look at FSD market cap. There is alot 140 million shares they can issue to bring the 1.3 million to 1.5 million. The market cap will not increase as the share price will adjust for the dilution
Renofund wrote:
Bella923 wrote:
You guys are all getting caught up in the math. Plain and simple, is 48 million dollars that FSD value in company stock. As to the conversion rate? The announcement was based on current outstanding shares of 3.5 million. Is this the actually number? NO. You guys don't think executives and insider with warrants and options will exercise? Of course. This will bring the share count higher. What ever the total share count is on a fully diluted basis of trpx, they will share 48 million. Plain and simple. If total fully diluted share count after exercise irons and warrant is 5 million, then each share is worth 48 million/5 is $9.60. so the final value all depends on the total diluted position of TRPX. Why would executive, make shareholder agree to this deal? Cause they probably have a SH$T load of options and they stand to benefit most as these options are penny on the dollar. Go through trpx Sec filling and you will see the granted options and warrant for the executives. If a deal is to good to be true, they it normal is to good to be true. Why do you think TRPX is not trading near the 13.74 that ppl talk about? Ppl buying TRPX now, Imo is basically buying a separate company and the share price will fluctuate independent of HUGE. If deal falls through, trpx will be back at $4. Who every buying TRPX now is paying a premium. Your upside is capped at the 48 million BO. Your downside could be unlimited if the deal falls thru. However, if HUGE in the next month goes to $2, you can do the math and figure it out and quickly realize buying HUGE at this price point would be the better deal. GLTA


look at TRPX’s current market cap.  Thanks.
 

 

Not what i was getting at.  Look at current market cap of TRPX vs. What we paid. There is value there

 

 

 

 

 

 

 

 

 

 




Bullboard Posts